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Internal deletions of the human interleukin-6 (IL-6) cDNA have been generated in the region encoding residues 29 to 42. Mutant proteins were 
produced by in vitro transcription-translation or in Escherichia co/i and tested for their biological activity using the hybridoma growth factor (HGF) 
assay or a transcriptional activation assay on human hepatoma cells. The folding of the mutants was also checked by immunoprecipitation with 
conformation-specific monoclonal antibodies. The results show that only residues 29 to 34 are crucial for IL-6 activity and that the fiest two amino 
acids are probably involved in the definition of the IL-6 active site. 
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1. INTRODUCTION 
Interleukin-6 (IL-6) is a cytokine produced and 
secreted by several cell types and active on a variety of 
target cells including B cells, T cells, cells of the 
hematopoietic lineage, hepatocytes and neurons (for 
reviews, see [1,2]). The mature form of IL-6 is a 184 
amino acids-long polypeptide which interacts at low af- 
finity with the IL-6 receptor (ILdR), an 80 kDa 
transmembrane protein present on the surface of target 
cells [3]. Transduction of the IL-6 message within the 
cell is triggered by the association of the IL-B/IL-6R 
complex with GP130, another transmembrane protein, 
which is accompanied by the appearance of high affini- 
ty IL-6 binding sites [4]. IL-6 is therefore believed to 
possess two distinct active sites which interact with 
PL-6R and GP130 respectively. 
IL-6 overproduction has been postulated as playing 
an important role in the pathogenesis of several 
neoplasic and autoimmune diseases 11,5]. It is therefore 
of practical importance to design IL-6 receptor an- 
tagonists which could be used as drugs in the therapy of 
diseases characterized by IL-6 overproduction. In the 
absence of a thorough understanding of the three- 
dimensional structure of IL-6, important information 
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on the composition of the active site of this cytokine has 
been gained by site-directed mutagenesis of the protein 
and the use of neutralizing monoclonal antibodies 
(mAb’s) [6-121. These studies have led to the conclu- 
sion that two distinct portions of the protein play an im- 
portant role in IL-6 structure and activity: (a) a region 
located towards the amino terminus and starting from 
the glutamine at position 28 [6]; (b) a carboxy-terminal 
domain from amino acid 154 to 184, which is believed 
to assume a-helical conformation [13]. 
In this paper we report the generation of a set of 
small internal deletions of human IL-6 spanning amino 
acids 29 to 42. Functional analysis of the mutant pro- 
teins and the recognition by conformation-specific 
monoclonal antibodies allow a precise definition of the 
amino terminal domain and the contribution of in- 
dividual amino acids to IL-6 folding and bioactivity. 
2. MATERIALS AND METHODS 
2. I . Chemicals 
L-[“S]methionine (> 37 TBq/mmol) was purchased from Amer- 
sham International. T7 RNA polymerase was obtained from BRL 
(Gibco BRL). 
2.2. Construction of human IL-6 internal deletions 
A &/II-Hind111 fragment carrying the T7 promoter upstream to 
the human IL-6.coding region from the plasmid pT7.7/IL-6 1141 was 
subcloned in plasmid pEMBL 131 [IS] to give plasmid pEMBL 
T7/IL-6. 
Internal deletions of human IL-6 were generated by 
oligonucleotide-directed mutagenesis on a single stranded DNA 
template. Single stranded pEiMi3L T7/IL-6 was prepared as described 
1151. 
Four oligonucleotides were synthesized to generate the following 
mutations: 
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A29-30 
631-34 
(He-A@ 
(Tyr-He-Leu-Asp) 
5 ‘TCGAGGATGTA-XST-XT- 
GTCAAI-I-CG 3’ 
5 ’ GCTGAGATGCCCCGA- 
ATTTGT’ITG 3’ 
A35-38 (Gly-He-Ser-Ala) 5 ’ GTCTCCTTKTCAGG- 
TCGAGGATG 3’ 
039-42 (Leu-Arg-Lys-Glu) 5 ’ TGTTACATGTGGCTG- 
AGATGCC 3 ’ 
Mutagenesis was performed according to Zoller and Smith 1161. In- 
dividual mutations were checked by direct sequencing with the 
dideoxy-chain terminator method [17]. Individual mutants were also 
transferred in the expression vector pT7.7, making use of the same 
restriction sites. 
2.3. Production of IL-6 mutant proteins 
IL-6 mutant proteins were produced in two alternative systems. 
(1) In vitro transcription and translation. Plasmids of the pEMBL 
series were San-linearized, transcribed with T7 RNA polymerase in. 
the same conditions as described by Fontaine et al. [lt] and subse- 
quently translated in a rabbit reticulocyte lysate in the presence of 
[%]methionine [12]. Translated proteins were analyzed on reducing 
17% SDS/PAGE followed by fluorography and autoradiography. 
The products were normalized either by densitomctric analysis of 
autoradiograms. or by cutting bands corresponding to individual pro- 
teins from the gel and measuring the radioactivity incorporated. 
These preparations were directly tested in the hybridoma growth fac- 
tor (HGF) assay and in the hepatoma assay. 
(2) Production in Escherichia co/i. Plasmids of the pT7.7 series 
were introduced in strain BL 21 (DE3) Lys E and recombinant IL-6 
mutant proteins wcx produced according to Arcone et al. 1141. This 
gave rise to large amounts of mutant IL-6 forms which were present 
in inclusion bodies. After renaturation in the presence of a 
glutathione redox system, proteins were quantified by a Bio-Rad pro- 
tein assay, visualized on non-reducing 17% SDS/PAGE. stained with 
Coomassie brilliant blue R-250 and immunodetected following 
transfer to nitrocellulose filters (not shown). These IL-6 mutants were 
used for competition experiments. 
2.4. IL-6 bioassays 
IL-6 assays in human hepatoma Hep 3B cells were performed ac- 
cording to Ganter et al. [18]. Plasmid 3’A-1211-146 CRP-CAT [I91 
carrying a fusion between a segment of C-reactive protein (CRP) pro- 
moter linked to the SV 40 early promoter and to the bacterial 
chloramphenicol acetyltransferase gene (CAT) was transfected in the 
cells using the calcium phosphate precipitation technique [20]. After 
15 h, precipitates were washed off and the cells were treated with 
equal amounts of in vitro synthesized wild-type or mutant IL-6. In- 
duction was carried out for 24 h; cell extracts and CAT assays were 
performed as described [tl] using 20 pg cell extracts incubated at 
37°C for 15 min. After autoradiography, individual spots were cut, 
eluted and the percentage of acetylated versus total [%]chloram- 
phenicol was determined. 
IL-6 hybridoma growth factor (HGF) assays were performed on the 
mouse I3 cell hybridoma 7TDl as described previously [22]. Briefly, 
cells were washed and seeded at a density of 2 x 10’ cells/microwell in 
a final volume of 0.2 ml. Cultures were incubated at 37% in 5% CO2 
in the presence of serial dilutions of the deletion mutants produced in 
reticulocyte lysate. After 4-5 days, the number of living cells was 
evaluated by measuring hexosaminidase levels as described [23]. 
2.5. Conformational ane~ysis oJ’ the IL-6.derived proteins by 
immuntiprecipitarion with anti-IL-6 mAb ‘s 
Immunoprecipitations were perfor!cd as described previously [9], 
Briefly, goat anti-mouse antibodies coupled to Sepharose were in- 
cubated overnight with a fixed amount of the mAb’s together with the 
deleted proteins, After washing, the Sepharose bound protein was 
dissolved in sample mix and subjected to SDS/PAGE under reducing 
conditions, followed by autoradiography. mAb 7 recognizes with a 
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higher affinity the unfolded wt hlL-6 than the native IL-6 and binds 
hexapeptides with amino acids Thr”2-Ala’JS of hIL-6 in common 
[24]. The neutralizing hIL-6 conformation-specific mAb 8 binds at 
the carboxy terminus [9]. lmmunoprecipitations with a rabbit anti- 
recombinant hlL-6 polyclonal antiserum in presence of Staphy/ococ- 
cus cureus Cowan I-protein A were used as a positive control [12]. 
3. RESULTS AND DISCUSSION 
Brakenhoff et al. [6] have reported that removal of 
the first 27 residues of the amino terminus of human 
IL-6 does not affect a certain number of bioactivities of 
this cytokine. However, deletion of the following 
residues leads to partial (28-29) or total (30-34) loss of 
activity. This region also interacts with conformation- 
specific neutralizing monoclonal antibodies (mAb’s) 
[9]; in particular, there is a subset of neutralizing mAb’s 
which recognize a composite pitope formed by amino 
acids in the 29-34 region and residues located at the 
carboxy-terminal end of the molecule [9]. 
In order to gain insight into the extension of this 
amino terminal domain we decided to generate internal 
deletions of two to four residues, leaving the rest of the 
molecule intact. The cDNA coding for mature hIL-6, 
preceded by the T7 polymerase promoter, was cloned in 
pEMBL 13 1 plasmid [IS], ssDNA was prepared and 
subjected to oligonucleotide directed mutagenesis [ 161. 
We generated four mutants 629-30, 431-34, d35-38 
and A39-42. The sequence of these mutants is 
schematically reported in Fig. 1. 
The various IL-6 wild-type and mutated genes were in 
vitro transcribed with T7 RNA polymerase and the 
resulting mRNAs were in vitro translated with rabbit 
reticulocyte lysate in the presence of L-[35S]methionine. 
Normalization of the translated proteins was carried 
out as described in section 2. In vitro translated proteins 
were used in two independent bioassays: (a) the HGF 
assay performed on the mouse B cell hybridoma 7TDl 
[22-231 (b) transcriptional activation of the IL-6 in- 
ducible human C-reactive protein (CRP) promoter ligk- 
ed to the CAT gene and transfected in human Hep 3 B 
cells [18]. 
As can be seen in Table I, all mutants behave similar- 
ly in both systems: Deletion of amino acids 3 l-34 leads 
to complete loss of activity; deletion of amino acids 
29-30 is accompanied by a loO- to 300-fold reduction of 
activity. Mutant 435-38 is only lo- to 20-fold less effi- 
cient than wild-type, whereas mutant 439-42 is only 
moderately impaired. These experiments, thus, define 
the boundaries of the amino-terminal domain between 
residues 29 and 38. 
Biologically inactive IL-6 mutants can still bind to the 
IL-6 receptor if the structure of the active site has only 
been partially destroyed and the folding of the protein 
has been conserved. We have tested this idea by produc- 
ing large amounts of the inactive mutants 429-30, 
431-34 and 435-38. Mutated genes were subcloned in 
the pT7.7 expression vector and then introduced in E. 
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NE2 20 29 30 31 32 33 34 35 36 31 30 39 CO 41 42 43 COOB 
vk TL-6 Gin ZLe ?&g Tyr 116 Isu Asp Gly ELe Saz Ala Lau Axg Lys Glu Thr 
.A 29-30 Gln Tyr I10 Ieu Asp Gly IL0 .Sar Ala hu Arg Lys Glu Tbp 
A 31-34 6l.n 110 J&g Qy 11% Sar ALa Lou ?ug Lye Glu T5x 
A 35-38 G3.n 119 z&g !lyz 11% Iau Al3p till bZJ L.yS c;lU m 
A 39-42 Gin IL% A.xy * 11% Lau Asp Gly 11% Sar &la Tleu 
Fig. 1. Amino acid sequence of wild-type and mutant IL-6 in the region spanning residues 28 to 42. For each mutant blank spaces correspond to 
deleted amino acids. 
co/i strain BL 21 (DE3) Lys E. Mutant proteins were ex- 
tracted from inclusion bodies and refolded as described 
in section 2. Competition experiments were performed 
in the Hep 3B bioassay using 2.5 ng/ml of wild-type E. 
co/i produced IL-6 [14] and 1: 1, 1:5 and 1:20 ratios of 
wild-type vs mutated proteins. The results shown in 
Fig. 2 clearly demonstrate that none of the inactive 
mutants is able to compete with IL-6. We obtained 
identical results when using a IO-fold excess of mutants 
to inhibit the HGF activity of the wild-type IL-6 (data 
not shown). 
Recently, a set of mAb’s has been developed which 
recognize different epitopes on the IL-6 molecule 
[9,24]. One of them, mAb 8, recognizes a group of 
carboxy-terminal residues better in the folded molecule. 
mAb 7 recognizes hexapeptides having IL-6 residues 
Thr’4’-Ala’45 in common. This epitope is located inter- 
nally in the folded molecule because wild-type IL-6 is 
not very reactive, unless it is subjected to heat inactiva- 
tion. We decided to use mAb 7 and mAb 8 as probes in 
immunoprecipitation experiments in order to obtain an 
idea of the molecule’s conformational make-up. In 
Table II we report the absolute level of im- 
munoprecipitation obtained with individual antibodies. 
We also include the results of immunoprecipitations 
with a rabbit polyclonal anti IL-6 antibody or without 
any antibody addition as positive and negative controls 
respectively. 
- Wild-type IL-6 is recognized at high efficiency by 
mAb 8 but not by mAb 7. 
Table 1 
Biological activity of the deletion mutants 
Proteins Relative HGF activity “C-Chlorampllenicol 
conversion 
WJ) (%) 
wt hlL-6 100 100 
A29-30 0.3 1-2 
631-34 40.3 0 
635-38 6 5-10 
A 39-42 7c 40-60 - 
The results are given for a same amount of proteins, determirled by 
densitoractry analysis of SDS-PAGE autoradiograms. 
- The active mutant A39-42 behaves imilarly, but here 
there is a moderate reaction with mAb 7, probably a 
sign of partial denaturatic f the protein. This result 
is in line with the slight dzc:case of activity that this 
mutant protein shows. 
- Mutant 431.-34 behaves inversely: its recognition by 
mAb 8 is considerably decreased and at the same time 
the mutant protein is precipitated efficiently by mAb 
7. This is clear evidence that this protein is 
denaturated, and explains its lack of activity. 
- For mutant A35-38 recognition by mAb 8 still 
prevails over recognition by mAb 7, but in this case 
the protein is only partially denaturated, which is in 
line witls its partial loss of activity. 
- The most interesting mutant is 429-30. Its im- 
munoreactivity is similar to that of d35-38 and 
therefore the protein is only partially unfolded, but its 
bioactivity is iO- to 20-fold lower than that of 
435-38. 
If we compare the two mutants 429-30 and A35-38, 
we find that they show the same degree of structural 
alteration, but have different biological activities. This 
Wild type Vector A29-30 A31-34 ASS-38 
Fig. 2. Competition of IL-6 activity by mutant proteins. Hep3B CRP- 
CAT bioasssys were performed with 2.5 ng/ml of wild-type E. co/i 
produced IL-6 as described in section 2. Competition experiments 
were carried out either with a ZO-fold excess of E. co/i proteins ex- 
tracted from cells carrying the expression vector without IL-6 insert 
jvector) or with a 1: 1, I:5 or 1:20 molar ratio of wild-type vs mutated 
proteins for each of the three mutants A2Y-30.631-34 and A3538. 
The resuks are represented as % of [‘4C]chloroamphenicol conver- 
sion. 
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Table II 
Conformational analysis of the deletion mutants 
Proteins Immunoprecipitation with or without 
anti IL-6 Ab 
polyclonal Ab mAb 7 mAb 8 
wt IL-6 + ++-I-+ - 
829-30 + + ff 
A3l-34 + ++ + 
A35-38 f + ++ 
A39-42 + + ++-I= - 
would suggest that the residues 29 and/or 30 participate 
more directly in the composition of the contact surface 
between IL-6 and the receptor or the GP 130 molecule. 
Two main conclusions can be drawn from this 
analysis: (a) in the amino terminal region of IL-6 only 
a limited set of amino acid residues (29-38) is required 
for optimal biological activity; (b) in this region it iz 
possible to distinguish between residues required to 
maintain IL-6 folding (31-38) and residues which also 
contribute to defining of the IL-6 active binding site (29 
or 30 or both), probably in conjunction with residues at 
the carboxy-terminal end of the molecule. We will be 
able to arrive at a more rigorous definition of the im- 
portance of this region with the analysis of single amino 
acid substitutions. 
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